toxylact: a04aa04 dolasetron

The first professional lActological database in the word

Dolasetron (ATC A04AA04) is a serotonin 5‑HT3 receptor antagonist used as an antiemetic in oncology and perioperative settings, with limited data in lactation but a theoretical low risk of clinically relevant infant exposure when used short‑term and with caution.medpedia.framar+2

Monograph title and scope

Title: Dolasetron (ATC A04AA04) – toxicological and lactological monograph for healthcare professionals.atcddd.fhi+1

This web‑page monograph provides a concise, clinically oriented overview of dolasetron within ATC class A04AA04 (serotonin 5‑HT3 antagonists), focusing on mechanism of action, indications, toxicological profile, and key considerations for use in breastfeeding women.atcddd.fhi+2

Pharmacological class and mechanism

Dolasetron is classified in the WHO ATC system as A04AA04, belonging to the subgroup of serotonin 5‑HT3 receptor antagonists indicated for prevention and treatment of nausea and vomiting. As a prodrug, it is rapidly converted to hydrodolasetron, the active metabolite that selectively blocks 5‑HT3 receptors in the chemoreceptor trigger zone and in the upper gastrointestinal tract, thereby inhibiting serotonin‑mediated emetogenic signaling. This pharmacodynamic profile explains its efficacy against chemotherapy‑induced and postoperative nausea and vomiting and aligns it with other 5‑HT3 antagonists such as ondansetron, granisetron, and tropisetron within the A04AA group.wikipedia+5

Indications and dosing (non‑lactation)

The primary approved indication for dolasetron is prophylaxis of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, as well as prevention and treatment of postoperative nausea and vomiting in adults and paediatric patients. Intravenous dosing commonly involves administration of a 5 ml injection solution diluted in 50 ml normal saline or 5% glucose, infused slowly over more than 15 minutes; oral dosing regimens (e.g. 100 mg orally 1 hour before chemotherapy in adults) are also used, with weight‑based dosing in children. Dosage recommendations may vary between jurisdictions, so local product information and institutional protocols should be consulted when planning therapy.mims+2

Contraindications and main toxicological concerns

Dolasetron is contraindicated in patients with known hypersensitivity to the drug or any excipients, and in those with pre‑existing atrioventricular block or significant conduction disturbances, due to its potential to prolong cardiac repolarization and precipitate arrhythmias. Key adverse reactions include headache, diarrhoea, fever, tachycardia, asthenia, constipation, sleep disturbances, dizziness, somnolence, and hot flushes, reflecting both central nervous system and gastrointestinal effects reported with 5‑HT3 antagonists. As with other agents in this class, serious but rare events such as marked QT interval prolongation, abnormal heart rhythm, and hypersensitivity reactions including anaphylaxis have been described, warranting ECG monitoring and clinical vigilance in high‑risk patients.hillman.upmc+2

Lactation safety – pharmacokinetic and clinical considerations

Specific quantitative data on dolasetron and hydrodolasetron transfer into human breast milk are lacking, and the medicine is not routinely listed among preferred antiemetics during breastfeeding. However, general lactation pharmacology principles suggest that medicines with relatively short half‑lives, high protein binding, and limited oral bioavailability at the doses present in milk tend to result in infant exposures below 10% of the maternal dose, a threshold often considered compatible with breastfeeding in the absence of intrinsic high toxicity. For 5‑HT3 antagonists, ondansetron is specifically cited as usable with caution in breastfeeding, with no reported adverse effects in breastfed infants and a property profile making significant milk transfer unlikely, which may serve as a surrogate class reference when considering dolasetron.medsafe+2

In the absence of direct human lactation studies for dolasetron, a cautious, case‑by‑case approach is recommended, avoiding use in premature or medically fragile infants and preferring better‑studied alternatives (e.g. ondansetron) where feasible. If dolasetron must be used in a breastfeeding woman for clear oncological or perioperative indications, short‑term, lowest‑effective‑dose therapy should be combined with infant monitoring for sedation, feeding changes, gastrointestinal disturbances, and signs of arrhythmia.sps+2

Practical recommendations for use in breastfeeding

For full‑term, otherwise healthy infants, short‑course dolasetron use in the mother may be considered when clinically necessary and when alternative antiemetics with better lactation evidence are unsuitable, but only after an individualised benefit–risk assessment. Strategies to minimise infant exposure include administering the maternal dose immediately after breastfeeding, favouring regimens of lowest effective dose and shortest duration, and avoiding repeated or prolonged courses. In infants at higher risk of drug‑related toxicity (preterm birth, significant cardiac disease, or renal impairment), dolasetron should generally be avoided during breastfeeding, and specialist consultation (clinical pharmacology, neonatology, or lactation medicine) is advisable if use is contemplated.mayoclinic+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.